BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37276496)

  • 21. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
    Cui L; Li ZG; Chai YH; Yu J; Gao J; Zhu XF; Jin RM; Shi XD; Zhang LP; Gao YJ; Zhang RD; Zheng HY; Hu SY; Cui YH; Zhu YP; Zou Y; Ng MHL; Xiao Y; Li JH; Zhang YH; He HL; Xian Y; Wang TY; Li CK; Wu MY;
    Am J Hematol; 2018 Jul; 93(7):913-920. PubMed ID: 29675840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991).
    Kamps WA; Bökkerink JP; Hählen K; Hermans J; Riehm H; Gadner H; Schrappe M; Slater R; van den Berg-de Ruiter E; Smets LA; de Vaan GA; Weening RS; van Weerden JF; van Wering ER; den der Does-van den Berg A
    Blood; 1999 Aug; 94(4):1226-36. PubMed ID: 10438710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.
    Stary J; Zimmermann M; Campbell M; Castillo L; Dibar E; Donska S; Gonzalez A; Izraeli S; Janic D; Jazbec J; Konja J; Kaiserova E; Kowalczyk J; Kovacs G; Li CK; Magyarosy E; Popa A; Stark B; Jabali Y; Trka J; Hrusak O; Riehm H; Masera G; Schrappe M
    J Clin Oncol; 2014 Jan; 32(3):174-84. PubMed ID: 24344215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
    Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
    J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of childhood acute Lymphoblastic leukemia in Egyptian children: a challenge for limited health resource countries.
    Tantawy AA; El-Rashidy FH; Ragab IA; Ramadan OA; El-Gaafary MM
    Hematology; 2013 Jul; 18(4):204-10. PubMed ID: 23394310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
    Schrappe M; Bleckmann K; Zimmermann M; Biondi A; Möricke A; Locatelli F; Cario G; Rizzari C; Attarbaschi A; Valsecchi MG; Bartram CR; Barisone E; Niggli F; Niemeyer C; Testi AM; Mann G; Ziino O; Schäfer B; Panzer-Grümayer R; Beier R; Parasole R; Göhring G; Ludwig WD; Casale F; Schlegel PG; Basso G; Conter V
    J Clin Oncol; 2018 Jan; 36(3):244-253. PubMed ID: 29148893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes for childhood acute lymphoblastic leukemia in low-middle income country before minimal residual disease risk stratification.
    Makkeyah S; Manzour A; Tantawy A; Mohamed A; Ebeid F; El-Sherif N; Abd El-Ghany S; Shawiesh M; Ali H; Sayed S; Ragab I
    Cancer Epidemiol; 2021 Dec; 75():102040. PubMed ID: 34649157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of therapeutic effectiveness of Nanfang ALL 99 protocol in childhood acute lymphoblastic leukemia patients].
    Wu XD; Li CF; He YL; Yang M; Zhang YM; Feng XQ; Teng ZL; Sun SM; Qian XH
    Zhonghua Er Ke Za Zhi; 2005 Dec; 43(12):890-3. PubMed ID: 16412348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study.
    Dujua AC; Hernandez FG
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):e116-e123. PubMed ID: 28085747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995.
    Tsuchida M; Ikuta K; Hanada R; Saito T; Isoyama K; Sugita K; Toyoda Y; Manabe A; Koike K; Kinoshita A; Maeda M; Ishimoto K; Sato T; Okimoto Y; Kaneko T; Kajiwara M; Sotomatsu M; Hayashi Y; Yabe H; Hosoya R; Hoshi Y; Ohira M; Bessho F; Tsunematsu Y; Tsukimoto I; Nakazawa S
    Leukemia; 2000 Dec; 14(12):2295-306. PubMed ID: 11187921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood--follow up after 9 years. Coall Study Group.
    Janka-Schaub GE; Harms D; Goebel U; Graubner U; Gutjahr P; Haas RJ; Juergens H; Spaar HJ; Winkler K
    Eur J Pediatr; 1996 Aug; 155(8):640-8. PubMed ID: 8839716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
    Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.
    Vandecruys E; Mondelaers V; De Wolf D; Benoit Y; Suys B
    J Cancer Surviv; 2012 Mar; 6(1):95-101. PubMed ID: 21630046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood.
    Toyoda Y; Manabe A; Tsuchida M; Hanada R; Ikuta K; Okimoto Y; Ohara A; Ohkawa Y; Mori T; Ishimoto K; Sato T; Kaneko T; Maeda M; Koike Ki; Shitara T; Hoshi Y; Hosoya R; Tsunematsu Y; Bessho F; Nakazawa S; Saito T
    J Clin Oncol; 2000 Apr; 18(7):1508-16. PubMed ID: 10735899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
    Pieters R; de Groot-Kruseman H; Van der Velden V; Fiocco M; van den Berg H; de Bont E; Egeler RM; Hoogerbrugge P; Kaspers G; Van der Schoot E; De Haas V; Van Dongen J
    J Clin Oncol; 2016 Aug; 34(22):2591-601. PubMed ID: 27269950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
    Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
    J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.